Buying the dip!

$DVAX has 4 large international COVID partners (Valneva, Clover, Medigen, Bio-E), some on the cusp of approval, with inactivated virus which is more effective against new variants, dependent on DVAX's proprietary adjuvant.

DVAX has the only 2 dose Hep-B vaccine on the market and has been gaining market share quarter after quarter.

DVAX has cash reserves close to 400 million - the recent dip after earnings were misleading as they are actually profitable.